Gilead Sciences 3Q Revenues: $1.4 billion (+30%) 3Q Earnings: $504 million (+27%) YTD Revenues: $3.9 billion (+25%)   YTD Earnings: $1.4 billion (+19%) Comments: The company achieved record revenues in the quarter. Growth was driven by the company’s antiviral franchise, with sales up 39% to $1.2 billion, including strong performances by Atripla and Truvada, with sales up 77% to $427.6 million and 34% to $549.1 million, respectively. Viread sales were $156.0 million in the quarter (...